Investors can be a fickle bunch. While they will happily reward strong
growth stories with eye-popping valuation multiples, they can be
demanding when it comes to the timing of that growth and the
marketing/investment spending that the company has to do to generate it.
That's my basic thesis on OraSure (OSUR),
as the shares of this rapid point-of-care (or PoC) testing specialist
seem undervalued relative to other diagnostics growth stories.
Read more here:
OraSure Seems Too Cheap Relative To Infectious Disease Opportunities
No comments:
Post a Comment